AlphAIalphai — Financial news for AI agents
MarketBeatFEB 204 min read$DTIL

John Alexander Kelly Sells 8,149 Shares of Precision BioSciences (NASDAQ:DTIL) Stock

Precision BioSciences CFO John Alexander Kelly sold 8,149 shares of the company's stock on February 18th for $3.84 per share, totaling $31,292. This transaction reduced his direct holdings by 6.08% to 125,883 shares. The article also notes significant institutional investment in Q4, mixed analyst ratings, and the company's current stock performance.

Original reporting
MarketBeat · MarketBeat
Published Feb 20, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 20, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
John Alexander Kelly Sells 8,149 Shares of Precision BioSciences (NASDAQ:DTIL) Stock — source image
Source · MarketBeat
Decision brief

The 30-second read

$DTILBearishMed
01

Why it matters

The insider sale, combined with bearish sentiment, suggests cautious investor outlook, potentially leading to short-term price weakness.

02

Market read

The news has moderate relevance for traders interested in biotech sector movements, especially those holding or considering positions in DTIL.

03

What to watch

Company fundamentals, upcoming catalysts, and broader market trends should be considered before making trading decisions.

Timing: short-term

Background

John Alexander Kelly, CFO of Precision BioSciences, sold 8,149 shares on February 18th, reducing his holdings by 6.08%. The company has seen mixed analyst ratings and significant institutional investment in Q4.

Company-level read

Ticker impact

$DTILBearishMedium confidence
Context

The news involves a significant insider transaction by the CFO, which can influence investor sentiment and stock perception.

Expected impact

Potential short-term decline or sideways movement due to insider selling and bearish sentiment.

Evidence & confidence

Insider sales can be perceived as a negative signal, especially if accompanied by bearish sentiment; however, the impact depends on overall market conditions and company fundamentals.

Market effects

Sector

The biotech sector may experience slight pressure due to negative sentiment around insider transactions.

Regional

Limited regional impact; primarily affects US biotech stocks.

Global

Minimal; specific to company and sector.

Counterpoint

What could challenge this read

Insider sales do not always indicate negative outlook; they could be for personal liquidity needs or diversification.

Key entities

  • Company
    Precision BioSciences

    A biotechnology company focused on genome editing technologies.

Read at source← All news

Related articles

AUG 20
$DTILMedAI 8/10

iECURE, Inc.: iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium

iECURE, Inc. announced that data from its OTC-HOPE clinical trial of ECUR-506 for neonatal-onset OTC deficiency will be presented at the SSIEM Annual Symposium. The presentation will include safety and metabolic control data. iECURE is a clinical-stage genome editing company, and Precision BioSciences (DTIL) is involved through its ARCUS nuclease technology.

finanznachrichten.de2 min
AUG 6
$DTILMed

PRECISION BIOSCIENCES INC (DTIL): Results of Operations and Financial Condition

PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease_final.htm EX-99.1 Document Exhibit 99.1 Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HB

SEC EDGAR 8-K6 min
MAY 27
$DTILHighAI 9/10

Precision BioSciences Shows First Evidence Of CccDNA Elimination In Hepatitis B Patients; Stock Up

Precision BioSciences (DTIL) reported first clinical biopsy evidence from its ELIMINATE-B study that PBGENE-HBV can eliminate and inactivate hepatitis B cccDNA. The company said cccDNA transcripts fell 10-fold after two doses, with remaining cccDNA showing indels that disrupt viral polymerase. It also reported pgRNA as a biomarker and durable HBsAg declines up to a year; 38 doses in 16 patients showed no dose-limiting toxicities.

rttnews.com6 min
AUG 20
$BAHighAI 9/10

U.S. approves in $4.5 billion KC-46A tankers sale to Qatar

The U.S. State Department approved a potential $4.5 billion sale of Boeing KC-46A tankers to Qatar, including up to four aircraft and related systems. Boeing, RTX, and Northrop Grumman are the principal contractors. The sale aligns with U.S. foreign policy and national security goals, according to the department.

investing.com2 min
AUG 20
$RIGHighAI 8/10

Transocean stock rises on $300M India drillship contract

Transocean Ltd. (RIG) shares rose 3% after securing a $300M contract with ONGC in India for a drillship, with operations starting in Q1 2027. The contract includes priced options for extension until 2031. Transocean operates 27 offshore drilling units, focusing on ultra-deepwater and harsh environment services.

investing.com1 min